<DOC>
	<DOCNO>NCT00092287</DOCNO>
	<brief_summary>The aim study compare efficacy safety lanreotide Autogel Sandostatin LAR Depot , see whether two 28-day prolonged release formulation produce similar clinical response patient carcinoid syndrome .</brief_summary>
	<brief_title>Comparison Lanreotide AutogelÂ® Sandostatin LAR Depot Treatment Clinical Symptoms Associated With Carcinoid Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Histologically confirm diagnosis neuroendocrine tumor carcinoid type . Documented evidence carcinoid syndrome ( flush and/or diarrhea ) attributable primary tumor lung , stomach midgut . Previous positive Octreoscan . World Health Organization ( WHO ) performance score low 2 . At baseline visit patient MUST satisfy follow criterion randomize receive study treatment : Stool and/or flush frequency great equal 3 episodes/day ( average minimum five consecutive day ) . Patients previously treat somatostatin analogue must discontinue treatment sufficient period time ( washout period least 7 day immediate release formulation 2 month prolong release formulation usually require ) . Compared `` control '' state treatment , patient must show clinically significant deterioration ( least two episode ) either symptom . For example , patient consider control previous treatment estimate stool frequency two episode per day , must achieve stool frequency least four episode per day ( average minimum five consecutive day ) . WHO performance score low 2 . VIPoma noncarcinoid tumor . Treatment interferon , chemotherapy radiotherapy give within 30 day prior inclusion , plan study . Radionuclide treatment within three month prior inclusion , plan study . Presence active malignant pathology ( except basal cellular carcinoma skin and/or situ carcinoma cervix/uterus ) . Surgical procedure embolization procedure ( without cytotoxic agent ) tumor within three month prior inclusion , plan study . Life expectancy le 6 month . Any investigational drug give within 30 day prior inclusion expect give study . No access telephone completion daily telephone diary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Carcinoid Syndrome</keyword>
	<keyword>Neuroendocrine Tumuors</keyword>
</DOC>